Is There Any Hope for Dynavax?

Dynavax (NAS: DVAX) is in a free fall. Shares have been cut in half today following a negative outcome from yesterday's Food and Drug Administration advisory committee review of its hepatitis B vaccine, Heplisav. The company's top drug candidate received an 8-5 vote against the sufficiency of its safety data, leading to huge doubts around its chances of approval next year. It's not clear how the FDA will react, and the possibility certainly still exists for an approval. However, as health care bureau chief Brenton Flynn explains in the video below, buying shares of Dynavax has become a gamble given the huge uncertainties that exist.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Is There Any Hope for Dynavax? originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.